Lixte Biotechnology Holdings Inc Cash Flow Conversion Efficiency
Lixte Biotechnology Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXTW) has a cash flow conversion efficiency ratio of -0.189x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-926.75K) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lixte Biotechnology Holdings Inc (2005–2024)
Cash flow conversion efficiency of Lixte Biotechnology Holdings Inc from 2005 to 2024. This chart illustrates how Lixte Biotechnology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lixte Biotechnology Holdings Inc share price for real-time trading data and today's change.
Lixte Biotechnology Holdings Inc Cash Flow Conversion Ratio Explained
Lixte Biotechnology Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lixte Biotechnology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their cash flow conversion efficiency. Also see Lixte Biotechnology Holdings Inc (LIXTW) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pure One Corporation Limited
AU:P1E
|
-0.273x |
|
Spiritus Mundi PLC
LSE:SPMU
|
N/A |
|
Biocept Inc.
NASDAQ:BIOCQ
|
-10.641x |
|
Minerals Exploration Limited
AU:MEX
|
N/A |
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
-1.051x |
|
Pyxis Tankers Inc
NASDAQ:PXSAW
|
0.033x |
|
Carbon Revolution Public Limited Ordinary Shares
NASDAQ:CREV
|
0.137x |
|
Shineco Inc
NASDAQ:SISI
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Lixte Biotechnology Holdings Inc from 2005 to 2024. Review financial agility of Lixte Biotechnology Holdings Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $827.22K | $-3.16 Million | -3.826x | -255.95% |
| 2023-12-31 | $3.99 Million | $-4.29 Million | -1.075x | -20.37% |
| 2022-12-31 | $5.17 Million | $-4.61 Million | -0.893x | -3.24% |
| 2021-12-31 | $4.79 Million | $-4.14 Million | -0.865x | -103.37% |
| 2020-12-31 | $5.01 Million | $-2.13 Million | -0.425x | +38.17% |
| 2019-12-31 | $2.43 Million | $-1.67 Million | -0.688x | -87.80% |
| 2018-12-31 | $4.13 Million | $-1.51 Million | -0.366x | +74.19% |
| 2017-12-31 | $995.04K | $-1.41 Million | -1.419x | +81.83% |
| 2016-12-31 | $214.76K | $-1.68 Million | -7.811x | -11.85% |
| 2015-12-31 | $312.33K | $-2.18 Million | -6.983x | -13.52% |
| 2014-12-31 | $265.86K | $-1.64 Million | -6.152x | -23.17% |
| 2013-12-31 | $236.27K | $-1.18 Million | -4.995x | -518.00% |
| 2012-12-31 | $1.49 Million | $-1.21 Million | -0.808x | +95.30% |
| 2011-12-31 | $79.02K | $-1.36 Million | -17.206x | -3090.42% |
| 2010-12-31 | $1.74 Million | $-936.39K | -0.539x | -9.91% |
| 2009-12-31 | $1.30 Million | $-638.44K | -0.491x | -126.56% |
| 2008-12-31 | $-323.55K | $-597.69K | 1.847x | +199.06% |
| 2007-12-31 | $376.93K | $-702.87K | -1.865x | -163.47% |
| 2006-12-31 | $626.56K | $-443.45K | -0.708x | -116.94% |
| 2005-12-31 | $-7.87K | $-32.87K | 4.177x | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more